Anti-TRAIL antibody [2E5]
| Name | Anti-TRAIL antibody [2E5] |
|---|---|
| Supplier | Abcam |
| Catalog | ab2219 |
| Prices | $382.00 |
| Sizes | 100 µg |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Clone | 2E5 |
| Applications | FA FC B/N |
| Species Reactivities | Human |
| Antigen | Recombinant soluble fragment, corresponding to amino acids 95-281 of Human TRAIL |
| Description | Mouse Monoclonal |
| Gene | TNFSF10 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
Apoptosis induced in JURKAT human T cell leukemia cell line by soluble recombinant human TRAIL is completely blocked by anti-human TRAIL (2E5). The neutralizing activity of the antibody 2E5 has been confirmed with various sources of soluble recombinant human TRAIL. A - medium B - recombinant TRAIL C - recombinant TRAIL + anti-human TRAIL (2E5; 0.06 µg/ml) D - recombinant TRAIL + anti-human TRAIL (2E5; 0.24 µg/ml) E - recombinant TRAIL + Isotype mouse IgG1 control
Product References
Complex changes in the apoptotic and cell differentiation programs during - Complex changes in the apoptotic and cell differentiation programs during
Sharova TY, Poterlowicz K, Botchkareva NV, Kondratiev NA, Aziz A, Spiegel JH, Botchkarev VA, Sharov AA. J Invest Dermatol. 2014 Dec;134(12):2873-82.
Synthetic triterpenoids cooperate with tumor necrosis factor-related - Synthetic triterpenoids cooperate with tumor necrosis factor-related
Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC. Cancer Res. 2005 Jun 1;65(11):4799-808.
TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia - TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia
Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T. Leukemia. 2002 Jan;16(1):67-73.